Table 1.

Summary of disease in the cervix and vagina of mice after 9 months with estrogen

Mouse genotypeSeverity of disease*
HCIN1CIN2CIN3MICLIC
CervixNTG17312
E6AP−/−211213
K14E6WT397857
K14E6WTE6AP−/−11221
VaginaHVAIN1VAIN2VAIN3MICLIC
NTG167
E6AP−/−118
K14E6WT9121521
K14E6WTE6AP−/−592

Abbreviations: H, hyperplasia; MIC, microinvasive cancer; VAIN, vaginal intraepithelial neoplasia.

  • *Cohorts of female mice of the indicated genotypes were treated with estrogen for 9 mo, and the reproductive tracts from every mouse were scored for the worst state (severity) of cervical (top half) or vaginal (bottom half of table) disease. The overall severity of disease between different genotypes was compared using a two-sided Wilcoxon rank sum test.

  • The shift in the severity of disease in K14E6WT transgenic mice is highly significant relative to NTG and E6AP−/− mice (P < 0.001).

  • Loss of E6AP results in a highly significant reduction in the severity of disease in K14E6WTE6AP−/− in the cervix (P < 0.001) and a significant reduction in the vagina (P = 0.05) relative to K14E6WT mice.